Published in Br J Pharmacol on May 01, 2005
Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors. Br J Pharmacol (2010) 0.99
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.88
Genetic variation and dopamine D2 receptor availability: a systematic review and meta-analysis of human in vivo molecular imaging studies. Transl Psychiatry (2016) 0.80
Inverse agonism and its therapeutic significance. Indian J Pharmacol (2011) 0.80
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem (1993) 4.52
G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem (1998) 2.92
Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci (1993) 2.59
Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A (1989) 2.51
Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem (1998) 1.51
Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol Chem (1982) 1.23
Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev (2001) 1.22
Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol (1992) 1.18
Determinants of alpha 2-adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G protein state. Mol Pharmacol (1994) 1.14
Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. Mol Pharmacol (1999) 1.09
A three-state receptor model of agonist action. Trends Pharmacol Sci (1997) 1.07
Conserved helix 7 tyrosine acts as a multistate conformational switch in the 5HT2C receptor. Identification of a novel "locked-on" phenotype and double revertant mutations. J Biol Chem (2002) 1.05
Differences in the ligand binding properties of the short and long versions of the D2 dopamine receptor. J Neurochem (1993) 1.04
Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity. Br J Pharmacol (2003) 1.04
Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations. Mol Pharmacol (1998) 1.03
Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation. J Neurochem (2001) 1.02
Inverse agonism and neutral antagonism at alpha(1a)- and alpha(1b)-adrenergic receptor subtypes. Mol Pharmacol (1999) 0.97
Effects of sodium on agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO cells and rat thalamus. Br J Pharmacol (2000) 0.96
Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci (2002) 0.96
Mechanisms of agonism and inverse agonism at serotonin 5-HT1A receptors. J Neurochem (2000) 0.92
Inverse agonist activity at the alpha(2A)-adrenergic receptor. Mol Pharmacol (2001) 0.91
Constitutive activity of a chimeric D2/D1 dopamine receptor. Mol Pharmacol (1997) 0.89
Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors. Biochem Pharmacol (2004) 0.86
Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Br J Pharmacol (1997) 0.86
Inverse agonist properties of atypical antipsychotic drugs. Biochem Pharmacol (2004) 0.85
Stimulated [35S]GTP gamma S binding by 5-HT1A receptor agonists in recombinant cell lines. Modulation of apparent efficacy by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.85
Constitutive activity and structural instability of the wild-type human H2 receptor. J Neurochem (1998) 0.85
Agonist action at D2(short) dopamine receptors determined in ligand binding and functional assays. J Neurochem (1997) 0.83
Characterization of dopaminergic compounds at hD2short, hD4.2 and hD4.7 receptors in agonist-stimulated [35S]GTPgammaS binding assays. Naunyn Schmiedebergs Arch Pharmacol (2000) 0.81
Constitutive coupling of a chimeric dopamine D2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs. J Pharmacol Exp Ther (2003) 0.77
Analysis of molecular determinants of affinity and relative efficacy of a series of R- and S-2-(dipropylamino)tetralins at the 5-HT1A serotonin receptor. Br J Pharmacol (2003) 0.77
Pathways for internalization and recycling of the chemokine receptor CCR5. Blood (2002) 1.38
The chemokine receptor, CCR5. Int J Biochem Cell Biol (2004) 1.04
Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity. Br J Pharmacol (2003) 1.04
Pharmacological characterization of the chemokine receptor, CCR5. Br J Pharmacol (2002) 1.00
Large-scale functional expression of WT and truncated human adenosine A2A receptor in Pichia pastoris bioreactor cultures. Microb Cell Fact (2008) 0.94
Domain swapping in the human histamine H1 receptor. J Pharmacol Exp Ther (2004) 0.91
Investigation of cooperativity in the binding of ligands to the D(2) dopamine receptor. Mol Pharmacol (2005) 0.91
Characterization of the endokinins: human tachykinins with cardiovascular activity. Proc Natl Acad Sci U S A (2003) 0.91
Mechanisms of ligand binding and efficacy at the human D2(short) dopamine receptor. J Neurochem (2002) 0.91
Diverse signalling by different chemokines through the chemokine receptor CCR5. Biochem Pharmacol (2006) 0.89
CCL3, acting via the chemokine receptor CCR5, leads to independent activation of Janus kinase 2 (JAK2) and Gi proteins. FEBS Lett (2004) 0.89
Mechanisms of internalization and recycling of the chemokine receptor, CCR5. Eur J Biochem (2004) 0.87
Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics. J Neurochem (2009) 0.86
Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors. Biochem Pharmacol (2004) 0.86
Inverse agonist properties of atypical antipsychotic drugs. Biochem Pharmacol (2004) 0.85
Mechanisms of agonist action at D2 dopamine receptors. Mol Pharmacol (2004) 0.85
A purified C-terminally truncated human adenosine A(2A) receptor construct is functionally stable and degradation resistant. Protein Expr Purif (2010) 0.84
Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor. Br J Pharmacol (2010) 0.82
Interaction of the D2short dopamine receptor with G proteins: analysis of receptor/G protein selectivity. Biochem Pharmacol (2003) 0.81
Agonist-dependent internalization of D2 receptors: Imaging quantification by confocal microscopy. Synapse (2007) 0.80
Allosteric effects of antagonists on signalling by the chemokine receptor CCR5. Biochem Pharmacol (2007) 0.80
The influence of G protein subtype on agonist action at D2 dopamine receptors. Neuropharmacology (2004) 0.80
Formation of oligomers by G protein-coupled receptors. Curr Opin Drug Discov Devel (2002) 0.80
Pharmacological analysis of a dopamine D(2Short):G(alphao) fusion protein expressed in Sf9 cells. FEBS Lett (2003) 0.78
Constitutive oligomerization of human D2 dopamine receptors expressed in Spodoptera frugiperda 9 (Sf9) and in HEK293 cells. Analysis using co-immunoprecipitation and time-resolved fluorescence resonance energy transfer. Eur J Biochem (2003) 0.78
Analysis of molecular determinants of affinity and relative efficacy of a series of R- and S-2-(dipropylamino)tetralins at the 5-HT1A serotonin receptor. Br J Pharmacol (2003) 0.77
Purification of the human G protein-coupled receptor adenosine A(2a)R in a stable and functional form expressed in Pichia pastoris. Curr Protoc Protein Sci (2012) 0.75
Radioligand binding analysis as a tool for quality control of GPCR production for structural characterization: adenosine A(2a)R as a template for study. Curr Protoc Protein Sci (2012) 0.75